A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients

BACKGROUND: Patients with hemophilia A are commonly treated with replacement recombinant factor VIII (rFVIII) products, which can be standard-acting or long-acting. Long-acting products have modifications, offering the potential for reduced dosing frequency while maintaining therapeutic benefit. Ext...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Songkai, Maro, Géraldine S., Desai, Vidhi, Simpson, Mindy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391132/
https://www.ncbi.nlm.nih.gov/pubmed/32820685
http://dx.doi.org/10.18553/jmcp.2020.20199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391132/
https://www.ncbi.nlm.nih.gov/pubmed/32820685
http://dx.doi.org/10.18553/jmcp.2020.20199

Ejemplares similares